Oppenheimer analyst Suraj Kalia raised the firm’s price target on Pulse Biosciences (PLSE) to $30 from $22 and keeps an Outperform rating on the shares. The firm notes the company reported Q4 revenues of $0.3M vs. its $0.3M estimate, following soft-tissue ablation platform launch in Q3 2025. Pulse received FDA approval to commence pivotal IDE study of nPulse Cardiac Catheter for paroxysmal-AF, to begin enrollment in next few months, completing Q4 2026. This follows feasibility study data, and while encouraging to say the least, results require confirmation in larger trials, Oppenheimer adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE:
- Pulse Biosciences Establishes New $60 Million ATM Program
- PLSE Upcoming Earnings Report: What to Expect?
- Pulse Biosciences price target raised to $30 from $25 at Mizuho
- Pulse Biosciences Reports Strong nPulse Atrial Fibrillation Study Results
- Pulse Biosciences says nPulse study demonstrates successful treatment